Skip to main content
. Author manuscript; available in PMC: 2024 Apr 1.
Published in final edited form as: Mol Carcinog. 2023 Jan 13;62(4):493–502. doi: 10.1002/mc.23501

Figure 1. Overview of the proposed DMR analysis on OCSCC plasma samples.

Figure 1.

A. The experimental design and overall analytical workflow for cfDNA methylation profiling on pre- and post-treatment OCSCC patient samples.

B. Pie charts showing the distribution of methylation status and genomic locations in the top detected DMRs.